Biological Treatment for Rheumatic Diseases
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Biopharmaceuticals".
Deadline for manuscript submissions: 30 December 2024 | Viewed by 1075
Special Issue Editor
Interests: connective tissue diseases; pathology of the extracellular matrix; growth factors; systemic sclerosis; juvenile idiopathic arthritis
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The implementation of biological drugs into the treatment of rheumatic diseases has opened new possibilities in the management of diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis. The development of "targeted" therapies that are more effective at inhibiting bone and joint destruction has significantly improved the life quality of patients. Some of these therapies lead to both the inhibition of locally ongoing lesions in the vicinity of the joints and the inhibition of generalized disease processes. However, not all patients respond positively to biological therapy. Moreover, the long-term use of biological drugs may be associated with a decrease in their efficacy as well as the occurrence of side effects related to the potential immunogenicity of these medicines. This is because biological drugs can induce an immune response and the synthesis of anti-drug antibodies (ADA, anti-drug antibodies). Therefore, it is important to understand the detailed mechanisms through which metabolic changes occur when using biological drugs. In this Special Issue, our goal is to bring together the results of expert research in this field, allowing us to better understand the effects of biological drugs on metabolic processes occurring in the body and provide an opportunity for medicines to be used more effectively in treating rheumatic diseases.
Dr. Kornelia Kuźnik-Trocha
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- biological drugs
- new treatment strategies
- antirheumatic agents
- arthritis
- rheumatic diseases
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.